EnPlusOne Biosciences, Inc.
EnPlusOne Bio is dedicated to delivering innovative RNA therapeutics by harnessing the power of enzymes for enzymatic synthesis of RNA oligonucleotides. Their mission is to enable scalable, sustainable, and next-generation solutions for emerging RNA therapeutics, with a focus on improving access and reducing costs through proprietary enzymatic platforms.
Industries
Nr. of Employees
small (1-50)
EnPlusOne Biosciences, Inc.
313 Pleasant Street Suite 4W Watertown, MA 02472
Products
Enzymatic RNA synthesis platform (platform technology)
A platform technology for enzymatic assembly of RNA oligonucleotides with support for site-specific and non-standard modifications, designed for development and scale-up for therapeutic applications.
Enzymatic RNA synthesis platform (platform technology)
A platform technology for enzymatic assembly of RNA oligonucleotides with support for site-specific and non-standard modifications, designed for development and scale-up for therapeutic applications.
Services
Synthesis services ranging from complete de novo RNA oligonucleotide manufacture to single-base or terminal extensions and site-specific modification incorporation.
Partnered research programs with academic institutes and funded agencies to develop immunotherapeutic and other RNA platforms.
Commercialization pathway from an academic invention through exclusive licensing and technology maturation.
Synthesis services ranging from complete de novo RNA oligonucleotide manufacture to single-base or terminal extensions and site-specific modification incorporation.
Partnered research programs with academic institutes and funded agencies to develop immunotherapeutic and other RNA platforms.
Commercialization pathway from an academic invention through exclusive licensing and technology maturation.
Expertise Areas
- Enzymatic RNA synthesis
- Oligonucleotide modification chemistry
- Bioprocess development and scale-up
- Purification process design for biologics
Key Technologies
- Template-independent enzymatic RNA synthesis
- Site-specific nucleotide modification
- Phosphorothioate backbone chemistry
- 2'- and 3'- ribose modifications
News & Updates
EnPlusOne Biosciences will present recent advances in their ezRNA platform at TIDES USA 2024 in Boston, bringing together scientists and companies focused on oligonucleotides and peptides in therapeutics.
Dan Ahlstedt, COO, will present the ezRNA platform at the 11th Annual Oligo Networking Conference at GSK’s Stevenage campus, discussing opportunities and challenges in oligonucleotide R&D and manufacturing.
Founders Daniel Wiegand and Jonathan Rittichier will participate in the 19th annual Oligonucleotide Therapeutics Society meeting in Barcelona, Spain, with a poster on enzymatic RNA synthesis technology.
The company achieved successful enzymatic synthesis of the antisense strand of Leqvio®, a treatment for hypercholesteremia, licensed from Alnylam Pharmaceuticals and marketed by Novartis.
The company announced a $10 million seed financing round led by Northpond Ventures, supporting development and scaling of their ezRNA platform.
EnPlusOne Biosciences will present recent advances in their ezRNA platform at TIDES USA 2024 in Boston, bringing together scientists and companies focused on oligonucleotides and peptides in therapeutics.
Dan Ahlstedt, COO, will present the ezRNA platform at the 11th Annual Oligo Networking Conference at GSK’s Stevenage campus, discussing opportunities and challenges in oligonucleotide R&D and manufacturing.
Founders Daniel Wiegand and Jonathan Rittichier will participate in the 19th annual Oligonucleotide Therapeutics Society meeting in Barcelona, Spain, with a poster on enzymatic RNA synthesis technology.
The company achieved successful enzymatic synthesis of the antisense strand of Leqvio®, a treatment for hypercholesteremia, licensed from Alnylam Pharmaceuticals and marketed by Novartis.
The company announced a $10 million seed financing round led by Northpond Ventures, supporting development and scaling of their ezRNA platform.